SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.

NCT05351788 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

110

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: SKB264
DRUG: KL-A167
DRUG: Carboplatin
DRUG: Cisplatin

Sponsor

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.